NCT01836185

A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment

Pharmacokinetics of Evacetrapib (LY2484595) in Subjects With Hepatic Impairment

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to measure how much of the drug gets into the bloodstream and how long it takes the body to remove it when given to participants with hepatic (liver) impairment compared to participants with normal hepatic function. Information about any side effects that may occur will also be collected. This study will last approximately 28 days, not including screening.

Conditions

• Hepatic Insufficiency

Interventions

Type	Name	Description
DRUG	Evacetrapib

Timeline

• Start date: 2013-04-01
• Primary completion: 2013-10-01
• Completion: 2013-10-01
• First posted: 2013-04-19
• Last updated: 2018-10-12
• Results posted: 2018-10-12

Locations

2 sites across 1 country: United States